glp-1 obesity drug news today october 23 2025 Perspectives from employers on the costs and issues associated with covering agonists for weight loss The Multi-Sector Impacts of GLP-1RA

This is particularly true with the GLP-1 receptor agonist drugs

The connection between obesity and CVD lies in dysfunctional adipose tissue, which releases various harmful bioactive lipids and pro-inflammatory factors (known as adipokines) that negatively affect the cardiovascular system

Brands capable of understanding those differences at platform level will be far better positioned to respond with evolving consumer expectations

Loss of lean muscle mass during rapid weight loss is a growing concern

IP(3) receptors preferentially associate with ER-lysosome contact sites and selectively deliver Ca(2+) to lysosomes

Excessive sun exposure, on the other hand, can accelerate the return of melanin production, diminishing the results over time